<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00882466</url>
  </required_header>
  <id_info>
    <org_study_id>EPO in AMI</org_study_id>
    <nct_id>NCT00882466</nct_id>
  </id_info>
  <brief_title>The Effect of Erythropoietin at the Time of Reperfusion in Acute Myocardial Infarction</brief_title>
  <official_title>Phase 4 Study of the Effect of Human Recombinant Erythropoietin at the Time of Reperfusion in Patients With Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of intravenous human recombinant&#xD;
      erythropoietin on the reperfusion injury at primary percutaneous coronary intervention in&#xD;
      patients with acute myocardial infarction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Creatinine kinase (CK), creatinine kinase-MB (CK-MB)</measure>
    <time_frame>4hr, 8hr, 12hr, 24hr, 48hr, 72hr</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infarct size assessed by cardiac MRI</measure>
    <time_frame>day 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>PCI only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>primary PCI only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human recombinant erythropoietin</intervention_name>
    <description>intravenous bolus injection of EPO (50unit/kg)</description>
    <arm_group_label>EPO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute myocardial infarction &lt;12hr&#xD;
&#xD;
          -  Age &gt;18yrs&#xD;
&#xD;
          -  First myocardial infarction&#xD;
&#xD;
          -  culprit lesion : proximal to mid left anterior descending artery&#xD;
&#xD;
          -  Baseline coronary flow : TIMI Grade 0~1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with previous myocardial infarction&#xD;
&#xD;
          -  History of thrombotic complication&#xD;
&#xD;
          -  History of cerebral infarction&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Increased hemoglobin level &gt;17g/dL&#xD;
&#xD;
          -  Patients with mechanical valve&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Ju Choi, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>April 15, 2009</study_first_submitted>
  <study_first_submitted_qc>April 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2009</study_first_posted>
  <last_update_submitted>April 16, 2009</last_update_submitted>
  <last_update_submitted_qc>April 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dong-Ju Choi</name_title>
    <organization>Seoul National University Bundang Hospital</organization>
  </responsible_party>
  <keyword>erythropoietin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

